Investor Relations

Corporate Profile

ZyVersa is a clinical stage specialty biopharmaceutical company with two licensed proprietary product platforms invented by top tier research scientists at University of Miami Miller School of Medicine. Our focus is on renal and inflammatory diseases which have a global total addressable market of around $14.5 billion and $65 billion, respectively.

The lead candidate in our renal pipeline is Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for focal segmental glomerulosclerosis (FSGS), an orphan renal disease. Renal cholesterol and lipid accumulation that occurs in FSGS and other glomerular diseases, such as Alport syndrome and diabetic kidney disease, contributes to structural damage to the kidneys’ filtration system leading to protein leaking into the urine (proteinuria) and disease progression. VAR 200 mediates removal of excess renal cholesterol and lipids that damage the kidneys and has potential to reduce proteinuria and delay disease progression.

Press Releases